HongShan reports portfolio licensing agreements with AstraZeneca, Boulevard Bio and Takeda

July portfolio update reports Dizal’s July 14 global license agreement with AstraZeneca, METiS’s agreement with Boulevard Bio, and Insilico Medicine’s cooperation with Takeda. These are portfolio-company agreements, not GP revenue, fund realizations or completed investor exits.